Discussing AAV-ligand Conjugates for Improved Efficacy & Distribution in CNS

Time: 4:00 pm
day: Day One


  • CNS delivery of gene therapy products remains challenging, in particular for achieving deep brain distribution of genetic materials
  • Chemical modification of AAV by new conjugation chemistry enables a rapid generation of rationally designed capsids
  • Generation of several conjugated AAV (coAAV) with improved in vivo transduction and biodistribution properties